{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"248.9","upperLimit":"1878","value":"683.6"},{"groupId":"OG001","lowerLimit":"760.1","upperLimit":"2050","value":"1248"},{"groupId":"OG002","lowerLimit":"1162","upperLimit":"2111","value":"1566"},{"groupId":"OG003","lowerLimit":"1425","upperLimit":"6454","value":"3032"},{"groupId":"OG004","lowerLimit":"111.8","upperLimit":"3595","value":"634.0"},{"groupId":"OG005","lowerLimit":"82.99","upperLimit":"616.7","value":"226.2"},{"groupId":"OG006","lowerLimit":"1449","upperLimit":"2693","value":"1976"},{"groupId":"OG007","lowerLimit":"962.5","upperLimit":"2059","value":"1408"},{"groupId":"OG008","lowerLimit":"824.6","upperLimit":"2653","value":"1479"},{"groupId":"OG009","lowerLimit":"505.0","upperLimit":"1447","value":"854.9"}]}],"title":"Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"371.5","upperLimit":"1995","value":"861.0"},{"groupId":"OG001","lowerLimit":"558.3","upperLimit":"2266","value":"1125"},{"groupId":"OG002","lowerLimit":"895.8","upperLimit":"1986","value":"1334"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG005","lowerLimit":"56.10","upperLimit":"5150","value":"537.5"},{"groupId":"OG006","lowerLimit":"1512","upperLimit":"3297","value":"2232"},{"groupId":"OG007","lowerLimit":"922.1","upperLimit":"2239","value":"1437"},{"groupId":"OG008","lowerLimit":"543.4","upperLimit":"3431","value":"1365"},{"groupId":"OG009","lowerLimit":"554.8","upperLimit":"1692","value":"968.8"}]}],"title":"Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time (0-24 hours) at which the concentration is at or above the lower limit of quantification. Unit of assessment was hour\\*nanogram per milliliter (hr\\*ng/mL).","dispersionType":"95% Confidence Interval","groups":[{"description":"SAR245409 capsule administered at a single oral dose of 30 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG000","title":"SAR245409 30mg"},{"description":"SAR245409 capsule administered at a single oral dose of 50 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG001","title":"SAR245409 50mg"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG002","title":"SAR245409 70mg"},{"description":"SAR245409 capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG003","title":"SAR245409 90mg"},{"description":"SAR245409 capsule administered twice, orally, at a dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG004","title":"SAR245409 30mg Twice Daily"},{"description":"SAR245409 capsule administered twice, orally, at a dose of 50 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG005","title":"SAR245409 50mg Twice Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: SAR245409 70mg Once Daily"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set. Here \"n\" signifies the number of subjects evaluable at the specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of SAR245409","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}